Shopping Cart

Imagion Biosystems Successfully Completes Toxicology Study

Imagion Biosystems Successfully Completes Toxicology Study

Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the successful completion of a toxicology safety study of its lead MagSense® nanoparticle formulation for the detection of HER2 metastatic breast cancer.
Read the announcement.

Related Articles

2023 AGM Resolution Overview

Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.